BEACHBODY CO INC/THE (BODY) Fundamental Analysis & Valuation

NYSE:BODY • US0734633094

8.14 USD
-0.17 (-2.05%)
Last: Mar 1, 2024, 08:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BODY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, BODY scores 1 out of 10 in our fundamental rating. BODY was compared to 74 industry peers in the Diversified Consumer Services industry. BODY may be in some trouble as it scores bad on both profitability and health. BODY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. BODY Profitability Analysis

1.1 Basic Checks

  • In the past year BODY has reported negative net income.
  • In the past year BODY has reported a negative cash flow from operations.
BODY Yearly Net Income VS EBIT VS OCF VS FCFBODY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 -100M -200M

1.2 Ratios

  • The Return On Assets of BODY (-38.15%) is worse than 78.46% of its industry peers.
  • BODY's Return On Equity of -93.91% is on the low side compared to the rest of the industry. BODY is outperformed by 75.38% of its industry peers.
Industry RankSector Rank
ROA -38.15%
ROE -93.91%
ROIC N/A
ROA(3y)-28.54%
ROA(5y)N/A
ROE(3y)-57.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BODY Yearly ROA, ROE, ROICBODY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 20 -20 -40 -60 -80

1.3 Margins

  • BODY's Gross Margin of 59.97% is fine compared to the rest of the industry. BODY outperforms 69.23% of its industry peers.
  • BODY's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BODY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.57%
GM growth 5YN/A
BODY Yearly Profit, Operating, Gross MarginsBODY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. BODY Health Analysis

2.1 Basic Checks

  • BODY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BODY has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for BODY is higher compared to a year ago.
BODY Yearly Shares OutstandingBODY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 100M 200M 300M
BODY Yearly Total Debt VS Total AssetsBODY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.41, we must say that BODY is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BODY (-1.41) is worse than 78.46% of its industry peers.
  • A Debt/Equity ratio of 0.20 indicates that BODY is not too dependend on debt financing.
  • The Debt to Equity ratio of BODY (0.20) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z -1.41
ROIC/WACCN/A
WACC7.92%
BODY Yearly LT Debt VS Equity VS FCFBODY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M

2.3 Liquidity

  • BODY has a Current Ratio of 0.76. This is a bad value and indicates that BODY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BODY has a worse Current ratio (0.76) than 78.46% of its industry peers.
  • A Quick Ratio of 0.57 indicates that BODY may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.57, BODY is doing worse than 83.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.57
BODY Yearly Current Assets VS Current LiabilitesBODY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BODY Growth Analysis

3.1 Past

  • BODY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -255.37%.
  • The Revenue for BODY has decreased by -26.83% in the past year. This is quite bad
  • BODY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.89% yearly.
EPS 1Y (TTM)-255.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-26.83%
Revenue growth 3Y-2.89%
Revenue growth 5YN/A
Sales Q2Q%-22.71%

3.2 Future

  • Based on estimates for the next years, BODY will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.40% on average per year.
  • The Revenue is expected to decrease by -10.52% on average over the next years. This is quite bad
EPS Next Y-28.34%
EPS Next 2Y24.72%
EPS Next 3Y18.4%
EPS Next 5YN/A
Revenue Next Year-25.14%
Revenue Next 2Y-15.96%
Revenue Next 3Y-10.52%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BODY Yearly Revenue VS EstimatesBODY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
BODY Yearly EPS VS EstimatesBODY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. BODY Valuation Analysis

4.1 Price/Earnings Ratio

  • BODY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BODY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BODY Price Earnings VS Forward Price EarningsBODY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BODY Per share dataBODY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

  • BODY's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.72%
EPS Next 3Y18.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BODY Dividend Analysis

5.1 Amount

  • BODY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BODY Fundamentals: All Metrics, Ratios and Statistics

BEACHBODY CO INC/THE

NYSE:BODY (3/1/2024, 8:04:47 PM)

8.14

-0.17 (-2.05%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)11-07
Earnings (Next)03-12
Inst Owners24.24%
Inst Owner Change-0.28%
Ins Owners367.36%
Ins Owner Change0%
Market Cap54.62M
Revenue(TTM)556.30M
Net Income(TTM)-132.50M
Analysts80
Price Target28.05 (244.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.28%
Min EPS beat(2)-54.06%
Max EPS beat(2)9.51%
EPS beat(4)1
Avg EPS beat(4)-25.58%
Min EPS beat(4)-54.06%
Max EPS beat(4)9.51%
EPS beat(8)3
Avg EPS beat(8)-24.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.98%
Min Revenue beat(2)-2.94%
Max Revenue beat(2)-1.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-2.94%
Max Revenue beat(4)2.43%
Revenue beat(8)4
Avg Revenue beat(8)3.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.88%
EPS NY rev (1m)0%
EPS NY rev (3m)3.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-21.5
EYN/A
EPS(NY)-5.95
Fwd EYN/A
FCF(TTM)-5
FCFYN/A
OCF(TTM)-3.7
OCFYN/A
SpS82.91
BVpS21.01
TBVpS-2.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.15%
ROE -93.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.97%
FCFM N/A
ROA(3y)-28.54%
ROA(5y)N/A
ROE(3y)-57.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.57%
GM growth 5YN/A
F-Score4
Asset Turnover1.6
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.59%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.57
Altman-Z -1.41
F-Score4
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)68.23%
Cap/Depr(5y)58.04%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-255.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-28.34%
EPS Next 2Y24.72%
EPS Next 3Y18.4%
EPS Next 5YN/A
Revenue 1Y (TTM)-26.83%
Revenue growth 3Y-2.89%
Revenue growth 5YN/A
Sales Q2Q%-22.71%
Revenue Next Year-25.14%
Revenue Next 2Y-15.96%
Revenue Next 3Y-10.52%
Revenue Next 5YN/A
EBIT growth 1Y51.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.85%
EBIT Next 3Y29.04%
EBIT Next 5YN/A
FCF growth 1Y74.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.09%
OCF growth 3YN/A
OCF growth 5YN/A

BEACHBODY CO INC/THE / BODY FAQ

Can you provide the ChartMill fundamental rating for BEACHBODY CO INC/THE?

ChartMill assigns a fundamental rating of 1 / 10 to BODY.


Can you provide the valuation status for BEACHBODY CO INC/THE?

ChartMill assigns a valuation rating of 0 / 10 to BEACHBODY CO INC/THE (BODY). This can be considered as Overvalued.


How profitable is BEACHBODY CO INC/THE (BODY) stock?

BEACHBODY CO INC/THE (BODY) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BODY stock?

The Earnings per Share (EPS) of BEACHBODY CO INC/THE (BODY) is expected to decline by -28.34% in the next year.